Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
Bristol Myers Squibb & Co (NYSE:BMY) posted fourth-quarter revenues of $12.34 billion, beating the consensus of $11.57 ...
Yahoo Finance27d
Handa Therapeutics Acquires FDA Approved Chronic Myeloid Leukemia Drug, PHYRAGO (dasatinib) Tablets
An estimated one-third of patients who require SPRYCEL ® treatment may also take gastric acid-reducing agents 1, which can reduce dasatinib's drug exposure by more than 40% when taken with a ...
Morningstar27d
Handa Therapeutics Acquires FDA Approved Chronic Myeloid Leukemia Drug, PHYRAGO (dasatinib) Tablets
PHYRAGO™ Represents the First and Only Improved Version of SPRYCEL® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / Handa ...
Pharmabiz25d
Handa Therapeutics acquires US FDA approved chronic myeloid leukaemia drug, Phyrago tablets from Nanocopoeia
An estimated one-third of patients who require Sprycel treatment may also take gastric acid-reducing agents, which can reduce dasatinib’s drug exposure by more than 40% when taken with a proton pump ...
PharmiWeb27d
Handa Therapeutics Acquires FDA Approved Chronic Myeloid Leukemia Drug, PHYRAGO (dasatinib) Tablets
PHYRAGO™ Represents the First and Only Improved Version of SPRYCEL ® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents PHYRAGO™ was granted Orphan-Drug Designation and has ...